Core Insights - The dialogue at the CPHI China exhibition highlighted the green transformation of the CDMO industry in China, emphasizing the shift from "manufacturing" to "intelligent manufacturing" through technological innovation and cost efficiency [1][3]. Group 1: Technological Innovations - Dr. Yang Minmin discussed the challenges of safety and environmental risks in the organic chemistry industry, leading to the exploration of new technologies like continuous flow and micro-packed bed [3]. - Drug Stone Technology has applied micro-packed bed technology in hydrogenation reactions for over a decade, enhancing selectivity and addressing the complexity of traditional process approvals [3]. - The company has accumulated experience in over 50 continuous flow technology projects, with more than 30% of R&D projects utilizing this technology, resulting in improved production efficiency and cost reduction [3]. Group 2: Cost and Efficiency Dynamics - Dr. Chen Zhihong highlighted that the continuous flow technology reduced the production cycle of drug intermediates from 40 days to 10 days, decreasing the footprint by 95% and solvent usage by over 50% [4]. - Over 60% of Drug Stone's Building Block business and 30%-40% of its CDMO business leverage new technologies, creating a positive cycle through standardized reactions that lower equipment costs [4]. - The Chinese pharmaceutical industry is projected to have an API export value of nearly $50 billion in 2024, facing pressures from domestic competition and carbon tariffs from Europe and the U.S. [4]. Group 3: Global Competitiveness and Challenges - Dr. Zhang Yantao noted that the focus of the industry has shifted from hardware construction to process management, reflecting improvements in green manufacturing capabilities [5]. - Drug Stone's overseas strategy involves a "local R&D + global delivery" model based on continuous flow technology, significantly reducing labor requirements and overcoming cost and environmental challenges in Europe and the U.S. [5]. - The total value of innovative drug license outs in China is expected to reach approximately $50 billion in 2024, urging Chinese CDMOs to accelerate their global expansion [5]. Group 4: Industry Insights and Future Vision - Dr. Yang Minmin envisioned transforming fine chemical plants into intelligent office environments, indicating a shift in industry paradigms [6]. - Dr. Zhang Yantao emphasized that advanced manufacturing technologies will inevitably take root in the largest manufacturing countries [6]. - The dialogue underscored the importance of embedding sustainability throughout the product development lifecycle to enhance business communication and competitiveness in the global pharmaceutical landscape [6].

公司总经理说，"目前，二期项目已经启动，预计今年10月份投产。届时，我们将成为全球产业链最 全、产能最大、竞争优势最明显的氯虫苯甲酰胺原药生产企业。每年可生产原药1万吨，年销售收入50 亿元、利税5亿元。" 两个月后，当地再度发文称，在仁和化工产业园，友道绿色植保产品连续流安全生产二期项目主体工程 完工，进入设备安装调试阶段。"这一项目总投资34.53亿元，依托豪迈集团自主研发的绿色连续流装备 及工艺，将建成全国精细化工领域低能耗、高环保、本质安全生产的示范基地。" 5月27日，山东省潍坊市高密市友道化学有限公司发生爆炸，应急管理部已介入。南都记者查询获悉， 事发公司涉足农药、医药领域，被列为当地高端化工产业典型代表，自2021年起连续三年人员规模不断 扩大。当地曾发文称，友道化学有限公司将建成全国精细化工领域低能耗、高环保、本质安全生产的示 范基地。 爆炸现场。 据公开报道，2021年8月，山东友道化学有限公司一期项目试生产开车正式启动。"此次仪式的召开，标 志着仁和化工产业园建成了第一家采用全连续流工艺的精细化工企业。" 2023年9月，当地发文称，作为高端化工产业的典型代表，山东友道化学有限公司依靠自主 ...

日前，江苏扬农化工集团有限公司(以下简称扬农集团)开发的微通道连续流催化合成吡啶杂环类产品清 洁生产技术及其工业化应用入选工业和信息化部公布的《第一批先进适用技术名单》。 吡啶酮是合成吡啶杂环类产品的重要中间体，原有的吡啶酮制备工艺复杂冗长、能耗高、污染大，改进 吡啶酮的制备工艺至关重要。 研究团队持续开展实验研究，经过一年多的努力，终于找到突破口。团队通过采用高效助剂，将繁冗复 杂的多步工序进行简化，不仅使吡啶酮收率和产品纯度得到显著提升，且大幅提高了产品的清洁性。据 测算，该工艺使得整个产品线含盐废水产生量降低10%。 吡啶及其衍生物是农药生产中一类重要原料及中间体，传统的吡啶杂环类产品生产工艺不仅成本高，还 会产生大量副产物，面临较大的安全和环境风险。为此，扬农集团于20世纪90年代末首创吗啉丙醛法工 艺，通过一系列工序制备吡虫啉、啶虫脒等吡啶杂环类产品，后经多年持续研究和技术改造，再次成功 开发出微通道连续流催化合成吡啶杂环类产品清洁生产技术并实现工业化应用，推动该类产品的绿色生 产工艺升级。 引入微通道连续流技术 传统吗啉丙醛法制吡啶杂环类产品工艺在中间体烯胺合成过程中存在强放热反应，安全风险较高。 ...